June 30, 2009
Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes
June 24, 2009
CTI Completes Pixantrone NDA Submission and Requests Priority Review
June 22, 2009
Responses after Completion of Therapy Increase Pixantrone Complete Remission/ Unconfirmed Complete Remission Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd line Therapy for Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma (NHL)
June 17, 2009
Cell Therapeutics Announces Preliminary Results of its Fixed Price Exchange Offers for Any and All of its $118.9 Million Convertible Notes Outstanding
 
View all news releases
June 2, 2009
Pixantrone produces high rates of complete and partial remissions even among aggressive NHL patients with extensive prior doxorubicin treatment or prior rituximab treatment
Press Release
June 1, 2009
Pixantrone significantly increases complete remissions, overall response rates, frequency of durable remissions and progression free survival in patients with relapsed and refractory aggressive non-Hodgkin’s lymphoma
Press Release
May 7, 2009
Q1 2009 Cell Therapeutics, Inc. Earnings Conference Call
Webcast
March 24, 2009
Special Meeting of Shareholders
Webcast
March 18, 2009
Washington Biotechnology & Biomedical Association Invest Northwest Conference
Webcast
CTI Subsidiaries:
Helpful Resources for Patients Read More
Help change the way Cancer is treated Clinical trials are crucial to the development of new therapies.